Jeremy Gaskill on moving from Humana to Geisinger Health Plan

Jeremy Gaskill, former Humana executive, joined Geisinger Health Plan (GHP) as president. He noted similar challenges in healthcare, but GHP's nonprofit status allows reinvestment in benefits and growth. GHP has 500,000 members and operates under Geisinger, a nonprofit with $9B revenue. Gaskill emphasizes disciplined investment in technology and provider partnerships.

Original reporting
Published Nov 4, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jeremy Gaskill on moving from Humana to Geisinger Health Plan — source image
Decision brief

The 30-second read

$HUMNeutralLow
01

Why it matters

Exec departure may cause modest market reaction; Geisinger’s private status limits direct trading relevance.

02

Market read

Executive change at Humana may cause slight stock pressure; limited broader market impact.

03

What to watch

Geisinger’s nonprofit status means no immediate earnings impact; Humana’s broader leadership team remains stable.

Relevance 5/10Novelty 5/10Timing: today

Background

The article profiles Jeremy Gaskill's transition from a senior role at Humana to leading Geisinger Health Plan, noting differences in scale and resources.

Company-level read

Ticker impact

$HUMNeutralMedium confidence
Context

Jeremy Gaskill, a longtime Humana executive, left to become president of Geisinger Health Plan.

Expected impact

potential slight downside as market prices the leadership transition

Evidence & confidence

Exec departures typically have limited immediate impact unless the executive is a CEO; Gaskill was a regional president, so effect is expected to be modest.

Market effects

Highlights challenges in Medicaid and Medicare Advantage for large insurers, but no direct sector shift.

May draw attention to health‑plan dynamics in Pennsylvania and the Midwestern states where Humana operates.

Limited; primarily a U.S. health‑insurance executive move.

Counterpoint

The move could be seen as a positive for Geisinger, signaling strong leadership, while Humana may view it as a routine turnover.

Key entities

  • Jeremy Gaskill

    Former central region president for Medicare at Humana, now president of Geisinger Health Plan

  • Humana

    Public health insurance company (ticker HUM) losing a senior executive

  • Geisinger Health Plan

    Nonprofit health plan owned by Geisinger health system

Related articles

$HUMMedAI 8/10

Humana Inc (HUM) (Q3 2026) Earnings Call Highlights: Raised EPS Outlook, Star Ratings

Humana Inc (HUM) raised its 2027 EPS outlook, citing cost savings, improved product positioning, and lower onboarding costs. The company expects higher core trends and Part D trends but faces Stars rating challenges. It plans to invest in growth and return capital to shareholders, with more details expected in December. Management also discussed cost pressures in its CenterWell PCO business and competitive dynamics in Medicare Advantage.

$HUMHighAI 8/10

Humana 3Q 2026: Revenue $41.16B, EPS $1.33 — 10-Q Summary

Humana reported 3Q 2026 revenue of $41.16B, up 26.1% YoY, driven by Medicare membership growth and higher premiums. Net income fell 16.9% to $162M, with EPS at $1.33. Insurance membership grew 20.3%, but the segment saw a $303M operating loss. CenterWell revenue rose 40.4% to $1.9B, though costs increased.

$HUMMedAI 8/10

Humana Inc. Q3 2026 Earnings Call Summary

Humana Inc. raised its 2026 adjusted EPS outlook due to strong operational performance and medical cost trends. The company is focusing on top quartile Star ratings and expects 2027 membership growth. A joint venture with BlackRock aims to improve balance sheet efficiency. Humana anticipates a 3%+ individual MA margin by 2028, with 2027 showing progress. The divestment of Gentiva is expected to close in Q4 2026, providing $900 million in pretax proceeds.

$HUMHighAI 8/10

Humana (HUM) Q3 2026 Earnings Call Transcript

Humana (HUM) reported Q3 2026 earnings with adjusted EPS of $17.17 YTD and a Q3 loss of $0.70, down from $3.24 YoY. Full-year adjusted EPS guidance raised to at least $9.50. GAAP EPS for Q3 was $1.33, down from $1.62 in 2025. The company expects $900M in pretax proceeds from Gentiva divestment. Medicare Advantage enrollment and Star ratings improved, but Part D cost trends are expected to rise to 14-15% in 2027.

$HUMMedAI 8/10

Humana Raises 2026 Profit Forecast

Humana reported better-than-expected quarterly results and raised its 2026 adjusted EPS forecast to at least $9.50 from $9. Medical and pharmacy costs rose less than expected. The company expects 3% pretax margins in Medicare Advantage by 2028. Shares fell 1.4% premarket. Year-to-date, the stock is up 61%.